Diaceutics (LON:DXRX) Earns Buy Rating from Canaccord Genuity Group

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reiterated by equities research analysts at Canaccord Genuity Group in a research note issued to investors on Tuesday, Marketbeat.com reports. They currently have a GBX 160 ($2.01) price objective on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 32.78% from the stock’s previous close.

Diaceutics Stock Down 2.8 %

DXRX stock opened at GBX 120.50 ($1.51) on Tuesday. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The firm’s 50-day simple moving average is GBX 121.99 and its 200 day simple moving average is GBX 126.21. The stock has a market cap of £101.79 million, a PE ratio of -4,016.67 and a beta of 0.58. Diaceutics has a fifty-two week low of GBX 84.50 ($1.06) and a fifty-two week high of GBX 136 ($1.71).

Diaceutics Company Profile

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.